2016-10-19

[#DIV28SUPER] Public comments wanted on DEA Scheduling the drug Kratom

Dear Colleagues – We wanted to let you know about an important development at the Drug Enforcement Administration regarding its notice of intent to place mitragynine and 7-hydroxymitragynine, two substances of the plant Mitragyna speciosa also referred to as kratom, in Schedule I.  According to our colleagues at the DEA, since publishing that notice, they have received a number of comments from members of the public.  Some of the commenters offered their opinions regarding the pharmacological effects of mitragynine and 7-hydroxymitragynine.  To allow consideration of these comments, as well as others, DEA has withdrawn its notice of intent to temporarily place Schedule I controls on kratom and is soliciting public comments until December 1, 2016.

 

DEA’s withdrawal notice and solicitation of comments may be found here: https://www.federalregister.gov/documents/2016/10/13/2016-24659/schedules-of-controlled-substances-temporary-placement-of-mitragynine-and-7-hydroxymitragynine-into

 

Should you have any questions, please contact the DEA’s Office of Congressional and Public Affairs at 202-307-7423.

 

 

Geoffrey Laredo

Senior Advisor to the Director

Office of Science Policy and Communications

National Institute on Drug Abuse

6001 Executive Blvd.

Bethesda, MD  20892

PLEASE NOTE NEW PHONE: 301.480.2850

mobile 202.329.3060

glaredo@nida.nih.gov

www.drugabuse.gov

http://www.drugfactsweek.drugabuse.gov

Connect with NIDA:
             

Science = Solutions

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

No comments:

Post a Comment